News
Press Releases and Media
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session
Detection Of Cardiac Amyloidosis, and More, Using SPECT/CT Imaging of Technetium-99m-Labeled Peptide P5+14 (At-05)
Reliability Of 124I-evuzamitide Imaging and Quantitative Agreement in Patients with AL and ATTR Systemic Amyloidosis
Automated Quantification of AL and ATTR Systemic Amyloid Burden Using 124I-evuzamitide, a Novel Pan-Amyloid Radiotracer
Diagnostic Performance of Cardiac and Whole-Body 124I-Evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis
Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis
Attralus Therapeutic AT-02 Receives Orphan Drug Designation from the U.S. FDA for the Treatment of ATTR Amyloidosis
Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis
Attralus Receives European Medicines Agency Committee for Orphan Medicinal Products (COMP) Positive Opinions for AT-02 for the Treatment of Both ATTR and AL Amyloidosis
Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)
Clinical Trial Design of AT-02 Phase 2 Open-Label Extension Study in Systemic Amyloidosis
Uptake of Iodine (124I) Evuzamitide in Patients with AL and ATTR Amyloidosis and Correlation with Echocardiographic Parameters
Automatic quantification of AL and ATTR amyloidosis disease burden using 124I-evuzamitide, a novel radiotracer
Relationship Between Myocardial Amyloid Load Measured by 124I-evuzamitide and Prognostic Staging Systems in Transthyretin Amyloid Cardiomyopathy
Characterizing Renal Involvement in Light Chain Amyloidosis on 124I-evuzamitide PET/MRI Imaging
Utilizing 124I-Evuzamitide PET/MRI to Elucidate the Relationship between Renal Dysfunction and Amyloid Deposition in Transthyretin Amyloid Cardiomyopathy
Quantitative Uptake of 124I-Evuzamitide on PET Correlates with Markers of Transthyretin Cardiac Amyloidosis, Quality of Life, and Functional Status
Cardiac Involvement in Rare Forms of Amyloidosis Assessed Using 124I-Evuzamitide PET/CT
Temporal Changes in Cardiac Amyloid Burden Assessed Using 124I-Evuzamitide PET/CT
Preliminary Evaluation of 99mTc-Labeled Peptide p5+14 (AT-05) for the Detection of Cardiopulmonary Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging
Relationship Between Myocardial 124I-evuzamitide Uptake and Extracellular Volume Fraction: A Cardiac PET/MRI Study
First-in-Human Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis
Changes in Organ-Specific Amyloid Load Assessed by Serial PET/CT Imaging of Iodine (124I) Evuzamitide – Correlation with Serum Biomarkers
Temporal Changes in the Renal Cytokine Profile in Response to AA Amyloidosis Induce Macrophage Infiltration Enabling Host-Mediated Targeting of Therapeutic Chimeric Antigen Receptor Macrophages (CARM)
Characterization of the Peptide-Antibody Fusion, AT-02- Studies to Support its Use as an Immunotherapy in Patients with Amyloidosis
Attralus Closes $56 Million Financing
Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology
Cardiac Amyloid Quantification Using 124I-Evuzamitide PET/CTCompared With 18F-Florbetapir PET/CT
Iodine-124-Evuzamitide PET/CT in Systemic Amyloidosis: Safety Evaluation & Reproducibility of Cardiac Uptake Quantitation
First-in-Human Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis
Relationship Between Myocardial 124I-evuzamitide Uptake and Cardiac Structure and Function: A Cardiac PET/MRI Study
Quantitative assessment of changes in cardiac and extracardiac amyloid load in patients with AL and ATTR amyloidosis, measured by PET/CT imaging using the pan-amyloid reactive radiotracer iodine (124I) evuzamitide
124I-evuzamitide PET/MR Unveils Hypertrophic Cardiomyopathy in a Patient with Renal AL Amyloidosis
I-124 Evuzamitide PET/CT is More Sensitive than Tc-99m Pyrophosphate forthe Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis
I-124 Evuzamitide PET/CT is More Sensitive than Tc-99m Pyrophosphate for the Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis
Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023
Development of Brain Shuttle Enabled AT-04, a Novel Peptibody That Binds Neuropathologic Fibrillar Aggregates
Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate
Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent
Quantification of Left Ventricular Amyloid in AL and ATTR Amyloid Cardiomyopathy: A Pilot 124I-p5+14 (AT-01) PET/CT and Echocardiography Study
Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis
Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis
AT-03 Demonstrated Pan-amyloid Binding and Stimulated the Removal of Amyloid Deposits through Macrophage-Mediated Phagocytosis
Preclinical characterization of AT-04, a pan-amyloid-binding Fc domain-peptide fusion, to serve as an opsonin for macrophage-mediated clearance of amyloid deposits
Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis
Attralus Presents In Vivo Preclinical Data for AT-02 Demonstrating Significant Amyloid Reduction at 18th International Symposium on Amyloidosis
Quantification of left ventricular amyloid using 124I-p5+14 (AT-01) and 18F-florbetapir positron emission tomography in AL and ATTR amyloidosis
Quantitative changes in organ-specific amyloid load in a patient with AL amyloidosis,measured by 124I-AT-01 PET/CT imaging, correlate with serumbiomarkers
Differentiation of ATTR amyloidosis based on abdominothoracic organ-specific uptakeof 124I-AT-01 (124I-p5+14)assessed by PET/CT imaging
A kit method for direct radiolabeling the amyloid reactive peptide p5+14 with technetium-99m (99mTc) for the detection of cardiac amyloidosis by SPECT/CTimaging
Detection of extracardiac amyloid in patients with ATTR amyloidosis by PET/CT imaging using the amyloidophilic radiotracer 124I-AT-01 (124I-p5+14)
Development of novel human chimeric antigen receptor-macrophages (CAR-M) as a potential therapeutic for amyloid clearance
Preclinical characterization of AT-02, a pan-amyloid-binding immunoglobulin-peptide fusion protein capable of enhancing phagocytosis and facilitating reduction of amyloid
Pan-amyloid reactivity of radioiodinated peptide 124I-AT-01 in patients with systemic amyloidosis demonstrated by PET/CT imaging
Results of the first-in-human PET/CT imaging study of the amyloid-reactive peptide 124I-AT-01 (124I-p5+14) for the detection of systemic amyloidosis
Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis
Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis
Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Final Results Of The First-In-Human Study Of The Amyloid-Reactive Peptide 124I-p5+14, (Iodine[124I] Evuzamitide; AT-01) For The Detection Of Systemic Amyloidosis
Repeat PET/CT Imaging of a Patient with Systemic Amyloidosis Using iodine (124I) evuzamitide (124I-p5+14) Identifies Organ-Specific Amyloid Regression
Attralus to Present New AT-01 Data at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
Fully Automated 3D Segmentation and Quantitation of the Amyloidophilic Radiotracer Iodine Evuzamitide (124i-P5+14, AT-01) in the Heart of Patients with Systemic Amyloidosis and Healthy Subjects
Detection of Cardiac Amyloidosis in Patients with Systemic AL and ATTR Amyloidosis Using Iodine Evuzamitide PET/CT Imaging and the Correlation with Serum NT-proBNP
Attralus Appoints James Testa as Vice President of Finance
Attralus is Developing a New Treatment for Systemic Amyloidosis
Patient Worthy
Podcast Edition: Jonathan Wall, PhD
OncologyTube
Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting
Detection of Systemic AL Amyloidosis by 124I-p5+14 PET/CT imaging – Providing the Complete Picture for Diagnosis
Pre-Clinical Characterization of a Novel Fusion Protein (AT-03), with Pan-Amyloid Binding and Removal
Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Attralus to Present New Data at 2021 American Society of Hematology Annual Meeting
Amyloidosis therapy PAR excellence? Attralus draws $116M series B
BioWorld
Attralus Closes $116 Million Series B Financing
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Business Insider
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Business Insider
Note: Source article is behind a pay wall.
BioSpace Movers & Shakers, July 30, 2021
BioSpace
Attralus Appoints Jake Bauer to Board of Directors
Synthesis of 99m Tc-labeled Peptide p5+14 for Detection of Cardiac Amyloidosis – Preclinical Studies in a Mouse Model
Poster Number 3007
Attralus Announces Presentation of Clinical Data on AT-01, a Novel Diagnostic for Systemic Amyloidosis, at the 2021 Society of Nuclear Molecular Imaging Meeting
Presentation: Multi-amyloid Reactivity of the Peptide Imaging Agent 124I-p5+14 (AT-01) in Patients with Amyloidosis
Clinical Utility of PET/CT Imaging with Peptide Imaging Agent 124I-p5+14 (AT-01) in Patients with Systemic Amyloidosis
Quantification of Peptide 124I-p5+14 (AT-01) Uptake in Patients with Systemic Amyloidosis
AT-01 Can Detect Amyloid Deposits in Heart of Asymptomatic Patients
FAP News Today
Detection and Differentiation of Cardiac Amyloidosis Using [124]I-P5+14 PET/CT Imaging and the Correlation with Clinical Biomarkers
Attralus Announces Presentation of Clinical Data on AT-01, a Novel, Potential First-in-Class Diagnostic for Systemic Amyloidosis at the 2021 American College of Cardiology Annual Meeting
Attralus Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
Imaging Agent Can Help Differentiate Between Amyloidosis Types
FAP News Today
Attralus Presents Clinical Data from Novel, Potential First-in-Class Diagnostic AT-01 for Systemic Amyloidosis at Virtual ASH 2020
Attralus to Present Clinical Data at Upcoming Virtual ASH 2020
Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A
Pharmaceutical Technology
Attralus Eyes Further Work on Therapeutic Candidates with New Funding
www.biospace.com
The Crunchbase News Briefing: Mon., Sept. 14
news.crunchbase.com
Attralus Raises $25M in Series A Financing
finsmes.com
Attralus Secures $25M Series A to Diagnose and Treat Amyloidosis
timmermanreport.com
Note: Source article is behind a pay wall.
Attralus debuts with $25M series A to tackle systemic amyloidosis
biocentury.com
Note: Source article is behind a pay wall.
Attralus Raises $25 Million to Transform Treatment for Patients with Systemic Amyloidosis
globalgenes.org
Attralus Presents Preclinical and Clinical Data at 17th International Symposium on Amyloidosis
Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
prnewswire.com
Aurora Bio, Inc Announces Clinical Data on Lead Program
businesswire.com
